After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Learn how personalized exercise routines can transform your COPD journey, enhance resilience, and improve your quality of ...

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...